J Breast Cancer.  2013 Sep;16(3):291-299. 10.4048/jbc.2013.16.3.291.

Silencing of Fanconi Anemia Complementation Group F Exhibits Potent Chemosensitization of Mitomycin C Activity in Breast Cancer Cells

• Yu J
• Zhao L
• Li Y
• Li N
• He M
• Bai X
• Yu Z
• Zheng Z
• Mi X
• Wang E
• Wei M

• KMID: 2286380
• DOI: http://doi.org/10.4048/jbc.2013.16.3.291

Abstract

PURPOSE
Fanconi anemia complementation group F (FANCF) is a key factor to maintaining the function of Fanconi anaemia/BRCA (FA/BRCA) pathway, a DNA-damage response pathway. However, the functional role of FANCF in breast cancer has not been elucidated. In the present study, we evaluated the chemosensitization effect of FANCF in breast cancer cells.
METHODS
We performed specific knockdown of the endogenous FANCF in breast cancer cells by transfecting the cells with an FANCF short hairpin RNA (shRNA) vector. Cell viability was measured with a Cell Counting Kit-8, and DNA damage was assessed with the alkaline comet assay. The apoptosis, cell cycle, and drug accumulation were measured by flow cytometric analysis. Protein expression levels were determined by Western blot analysis, using specific antibodies.
RESULTS
The analyses of two breast cancer cell lines (MCF-7 and MDA-MB-435S) demonstrated that the FANCF shRNA could effectively block the FA/BRCA pathway through the inhibition of Fanconi anemia complementation group D2 ubiquitination. Moreover, FANCF silencing potentiated the sensitivity of cells to mitomycin C (MMC), where combined FANCF shRNA/MMC treatment inhibited cell proliferation, induced S-phase arrest, apoptosis, and DNA fragmentation, and reduced the mitochondrial membrane potential, compared with MMC treatment alone.
CONCLUSION
Taken together, this study demonstrates that the inhibition of FANCF by its shRNA leads to a synergistic enhancement of MMC cytotoxicity in breast cancer cells. These results suggest that the inhibition of the FA/BRCA pathway is a useful adjunct to cytotoxic chemotherapy for the treatment of breast cancer.

Keyword

Breast neoplasms; Fanconi anemia complementation group F protein; Mitomycin C; Tumor cell line

MeSH Terms

Apoptosis
Blotting, Western
Breast
Breast Neoplasms
Cell Count
Cell Cycle
Cell Line
Cell Line, Tumor
Cell Proliferation
Cell Survival
Comet Assay
Complement System Proteins
DNA Damage
DNA Fragmentation
Fanconi Anemia
Fanconi Anemia Complementation Group F Protein
Membrane Potential, Mitochondrial
Mitomycin
RNA, Small Interfering
Ubiquitin
Ubiquitination
Complement System Proteins
Fanconi Anemia Complementation Group F Protein
Mitomycin
RNA, Small Interfering
Ubiquitin

Figure

• 

  Figure 1 Fanconi anemia complementation group F (FANCF) levels and Fanconi anemia, complementation group D2 (FANCD2) ubiquitination in cells. MCF-7 and MDA-MB-435S cells were transfected with FANCF shRNA and control shRNA (scrambled shRNA) for 24 or 48 hours. (A) and (B) is the Western blot analysis for detecting the FANCF and FANCD2 expression changes. Then protein was extracted for performing Western blotting with anti-FANCF or anti-FANCD2 antibodies (FANCD2-L=monoubiquitinated; FANCD2-S=nonubiquitinated). β-Actin was simultaneously immunodetected to verify equal loading of cell lysates. (A) FANCF and (B) FANCD2 blots representative of three independent experiments are presented. (C) The cell viability was determined by the CCK-8 kit. *p<0.05 versus cells with control shRNA at 48 hours; †p<0.05 versus cells with control shRNA at 24 hours.

• 

  Figure 2 Changes of proliferation in mitomycin C (MMC)-treated cells. Dose-response curve of FANCF silencing in cell viability assay with or without MMC. (A) MCF-7 and (B) MDA-MB-435S cells were transfected with FANCF shRNA for 48 hours, and then treated with MMC for 24 hours. The results were expressed as a percentage relative to the control (untreated with MMC). Each point on the graph represents the means±SD.

• 

  Figure 3 DNA damage measurement. (A) Comet assay showed detectable comet tails when visualized under a fluorescent microscope, indicative of DNA damage. (B) Semiquantitation analysis of the results in (A) values of tail length (means±SD) were obtain from random selected 50 cells. *p<0.05 versus untreated cells; †p<0.05 versus cells treated with control shRNA and mitomycin C. FANCF=Fanconi anemia complementation group F; MMC=mitomycin C.

• 

  Figure 4 Cell cycle analysis. (A) MCF-7 and MDA-MB-435S cells were synchronized by culturing in serem free media for 72 hours, followed by incubation in serem-containing media for 24 hours and subsequent treatment with either mitomycin C (MMC) or MMC plus Fanconi anemia complementation group F (FANCF) shRNA or control shRNA for 24 hours. Distribution of cells in different phases of cell cycle was analyzed by propidium iodide staining followed by flow cytometry. One representative experiment is shown. Enhanced accumulation of MCF-7 and MDA-MB-435S cells in the S-phase of the cell cycle was observed after cotreatment with MMC and FANCF shRNA. (B) The bar diagrams indicate the distribution of the cells in the different phases of the cell cycle. Data are means±SD of three independent experiments in triplicates.

• 

  Figure 5 The apoptosis detection in cells. (A) Apoptosis of cells were measured using FACScan after staining with FITC-annexin V and propidium iodide. Cells in the lower right-hand quadrant are early apoptotic cells with exposed phosphatidylserine (FITC-annexin V-positive) but intact membrane (PI-negative) and (B) is the quantification of apoptosis in the indicated cell lines. *p<0.05 versus untreated cells; †p<0.05 versus cells treated with control shRNA and mitomycin C. FANCF=Fanconi anemia complementation group F; MMC=mitomycin C; FITC=fluorescence isothiocyanate; PI=propidium iodide.

• 

  Figure 6 ΔΨm FACS detection in cells. (A) The cells were stained with 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbe nzimidazolylcarbocyanine iodide (JC-1) fluorescence dye, and the change in ΔΨm was examined by FACS. (B) Change in ΔΨm was examined by fluorescence microscopy. (C) Densitometric analysis was done for fraction of cells. Graphs show means±SD of three independent experiments. *p<0.05 versus untreated cells; †p<0.05 versus cells treated with control shRNA and mitomycin C. FANCF=Fanconi anemia complementation group F; MMC=mitomycin C.

Reference

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55:74–108.

2. Aldabbagh K, Pouderoux S, Roca L, Poujol S, Fabbro M, Romieu G, et al. Etoposide, mitomycin, and methotrexate combination in heavily treated breast cancer: a retrospective study. Breast Cancer. 2012; 19:16–22.

3. Urruticoechea A, Archer CD, Assersohn LA, Gregory RK, Verrill M, Mendes R, et al. Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer. Br J Cancer. 2005; 92:475–479.

4. Celli CM, Jaiswal AK. Role of GRP58 in mitomycin C-induced DNA cross-linking. Cancer Res. 2003; 63:6016–6025.

5. McHugh PJ, Spanswick VJ, Hartley JA. Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. Lancet Oncol. 2001; 2:483–490.

6. Bagby GC, Alter BP. Fanconi anemia. Semin Hematol. 2006; 43:147–156.

7. Auerbach AD. Fanconi anemia and its diagnosis. Mutat Res. 2009; 668:4–10.

8. Stoepker C, Hain K, Schuster B, Hilhorst-Hofstee Y, Rooimans MA, Steltenpool J, et al. SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype. Nat Genet. 2011; 43:138–141.

9. Bogliolo M, Lyakhovich A, Callén E, Castellà M, Cappelli E, Ramírez MJ, et al. Histone H2AX and Fanconi anemia FANCD2 function in the same pathway to maintain chromosome stability. EMBO J. 2007; 26:1340–1351.

10. Lyakhovich A, Surrallés J. New roads to FA/BRCA pathway: H2AX. Cell Cycle. 2007; 6:1019–1023.

11. Olopade OI, Wei M. FANCF methylation contributes to chemoselectivity in ovarian cancer. Cancer Cell. 2003; 3:417–420.

12. Chen Q, Van der Sluis PC, Boulware D, Hazlehurst LA, Dalton WS. The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. Blood. 2005; 106:698–705.

13. Narayan G, Arias-Pulido H, Nandula SV, Basso K, Sugirtharaj DD, Vargas H, et al. Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer. Cancer Res. 2004; 64:2994–2997.

14. Chen CC, Taniguchi T, D'Andrea A. The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents. J Mol Med (Berl). 2007; 85:497–509.

15. Singh NP, McCoy MT, Tice RR, Schneider EL. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res. 1988; 175:184–191.

16. Léveillé F, Blom E, Medhurst AL, Bier P, Laghmani el H, Johnson M, et al. The Fanconi anemia gene product FANCF is a flexible adaptor protein. J Biol Chem. 2004; 279:39421–39430.

17. Kowal P, Gurtan AM, Stuckert P, D'Andrea AD, Ellenberger T. Structural determinants of human FANCF protein that function in the assembly of a DNA damage signaling complex. J Biol Chem. 2007; 282:2047–2055.

18. Siegel D, Beall H, Senekowitsch C, Kasai M, Arai H, Gibson NW, et al. Bioreductive activation of mitomycin C by DT-diaphorase. Biochemistry. 1992; 31:7879–7885.

19. Gupta SC, Kim JH, Prasad S, Aggarwal BB. Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev. 2010; 29:405–434.

20. Tamm I, Schriever F, Dörken B. Apoptosis: implications of basic research for clinical oncology. Lancet Oncol. 2001; 2:33–42.

21. D'Andrea AD. The Fanconi Anemia/BRCA signaling pathway: disruption in cisplatin-sensitive ovarian cancers. Cell Cycle. 2003; 2:290–292.

22. Burkitt K, Ljungman M. Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin. Mol Cancer. 2008; 7:24.

23. Hortobagyi GN. Mitomycin-C in breast cancer. Semin Oncol. 1985; 12:65–70.

24. Godfrey TE. Mitomycin C in advanced breast cancer: an update. Semin Oncol. 1988; 15:71–73.

25. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646–674.

26. Jiang YY, Wang HJ, Wang J, Tashiro S, Onodera S, Ikejima T. The protective effect of silibinin against mitomycin C-induced intrinsic apoptosis in human melanoma A375-S2 cells. J Pharmacol Sci. 2009; 111:137–146.

27. Moldovan GL, D'Andrea AD. How the fanconi anemia pathway guards the genome. Annu Rev Genet. 2009; 43:223–249.

28. Barroso E, Pita G, Arias JI, Menendez P, Zamora P, Blanco M, et al. The Fanconi anemia family of genes and its correlation with breast cancer susceptibility and breast cancer features. Breast Cancer Res Treat. 2009; 118:655–660.